pharma · No medical condition. · Generalized Myasthenia Gravis
Lacuna Pharma Pty Ltd
Lacuna Pharma Pty is a pharma organization headquartered in Colmenar Viejo, AU. Primary therapeutic focus areas include No medical condition., Generalized Myasthenia Gravis, No therapeutic indication in the current trial
Phase 2 · other · Glioblastoma
CAN-201 NDG is a Phase I/II open-label study sponsored by Lacuna Pharma Pty Ltd investigating Azeliragon in combination with standard-of-care concurrent radiation and temozolomide (TMZ) in newly diagnosed glioblastoma patients. Azeliragon is being evaluated as an adjunctive agent to conventional chemoradiation, with th
Internal code CAN-201 NDG
CAN-201 NDG is a Phase I/II open-label study sponsored by Lacuna Pharma Pty Ltd investigating Azeliragon in combination with standard-of-care concurrent radiation and temozolomide (TMZ) in newly diagnosed glioblastoma patients. Azeliragon is being evaluated as an adjunctive agent to conventional chemoradiation, with the trial designed to assess safety and preliminary therapeutic efficacy. The program represents an investigational approach to glioblastoma, one of the most aggressive primary brain malignancies, where standard treatment remains radiation plus TMZ despite poor long-term outcomes. The trial is currently active and enrolling; specific mechanism of action for Azeliragon in this indication has not been disclosed. Temozolomide, the backbone comparator, is an established oral alkylating agent approved globally (US, EU, Australia) as standard-of-care for glioblastoma since 2000. The combination strategy suggests Lacuna is exploring whether Azeliragon can enhance or synergize with conventional therapy. No regulatory approvals, peak sales projections, or partnership arrangements have been disclosed for this program.
Glioblastoma remains one of oncology's most intractable challenges, with median overall survival of approximately 15 months despite maximal surgical resection, radiation, and chemotherapy. The disease represents a significant unmet medical need: standard-of-care has remained largely unchanged for over two decades, and most patients develop recurrent disease within 12 months. Any agent demonstrating safety and efficacy when combined with standard chemoradiation could represent a meaningful advance, particularly if it improves progression-free or overall survival without excessive toxicity. The patient population, while relatively small (approximately 10,000–15,000 new cases annually in developed markets), faces dire prognosis and limited options, creating strong clinical motivation for novel combination approaches. From a commercial perspective, a successful glioblastoma therapeutic could command premium pricing given unmet need and orphan-like disease characteristics. The competitive landscape includes established standards (TMZ, radiation) but few approved adjunctive or combination agents specifically for newly diagnosed disease, suggesting limited direct competition for a differentiated combination strategy. Regulatory pathways for glioblastoma therapies have shown flexibility (e.g., accelerated approval frameworks), potentially enabling faster development timelines if early signals are compelling.
Azeliragon: Mechanism of action, target, and molecular modality not yet disclosed in available facts. Route of administration not specified. Therapeutic classification and related therapies cannot be confirmed without additional data.
Temozolomide (APO-TEMOZOLOMIDE and other brands):
Also known as: GBM, GBM (glioblastoma), WHO grade IV glioma, glioblastoma (disease), glioblastoma multiforme, glioblastoma multiforme (disease)
Prevalence: Point prevalence: 1-9 / 100 000 (Worldwide) — source: Orphanet, validated.
The most malignant astrocytic tumor (WHO grade IV). It is composed of poorly differentiated neoplastic astrocytes and it is characterized by the presence of cellular polymorphism, nuclear atypia, brisk mitotic activity, vascular thrombosis, microvascular proliferation and necrosis. It typically affects adults and is preferentially located in the cerebral hemispheres. It may develop from diffuse astrocytoma WHO grade II or anaplastic astrocytoma (secondary glioblastoma, IDH-mutant), but more frequently, it manifests after a short clinical history de novo, without evidence of a less malignant precursor lesion (primary glioblastoma, IDH- wildtype). (Adapted from WHO)
ClinicalTrials.gov lists 877 registered studies for Glioblastoma (AACT aggregate).
Phase breakdown: NA (252), PHASE2 (223), PHASE1 (206), PHASE1/PHASE2 (86), EARLY_PHASE1 (49), PHASE3 (45), PHASE2/PHASE3 (11), PHASE4 (5)
Common investigational therapies:
Disease data sourced from MONDO Disease Ontology (MONDO:0018177), Orphanet — glioblastoma, NCT00001148, NCT00001171, NCT00009035, NCT00028158, NCT00029783, AACT (ClinicalTrials.gov aggregate), ClinicalTrials.gov, Open Targets Platform (CC BY 4.0).
CAN-201 NDG Phase I/II enrollment ongoing
Open-label study assessing safety and preliminary efficacy of Azeliragon combined with concurrent radiation and temozolomide in newly diagnosed glioblastoma.
The competitive landscape for glioblastoma is dominated by the standard-of-care regimen of radiation plus temozolomide, which has remained the backbone for over 20 years. Temozolomide is manufactured by multiple sponsors including Merck Sharp & Dohme, Accord Healthcare, Hexal AG, Sandoz, Teva, and others across US, EU, and Australian markets. The facts list several approved oncology agents (Imbruvica, Afinitor, Kyprolis, Ofev, Paclitaxel Accord, Inlyta, Vyxeos Liposomal, Unituxin, Lynozyfic, Lysodren) as competitors, though their specific roles in glioblastoma treatment are not detailed in the available data. Most of these appear to be approved for other indications (hematologic malignancies, renal cell carcinoma, idiopathic pulmonary fibrosis) rather than glioblastoma specifically. The absence of widely adopted adjunctive agents for newly diagnosed glioblastoma suggests limited direct competition for Azeliragon's proposed combination approach, though the field has seen numerous investigational combinations and checkpoint inhibitors in clinical development. Lacuna's strategy of combining Azeliragon with standard chemoradiation positions the program as an enhancement strategy rather than a replacement therapy, which may reduce competitive friction but requires demonstration of additive benefit without unacceptable toxicity.
| Therapy | Company | Mechanism | Status |
|---|---|---|---|
| PFIZER AUSTRALIA PTY LTD | Pfizer Australia Pty Ltd | — | approved |
| IMBRUVICA | Janssen-Cilag Pty Ltd | — | approved |
| AFINITOR | Novartis Pharmaceuticals | — | approved |
| LYSODREN | S.A. | — | approved |
| INLYTA | Pfizer Australia Pty Ltd | — | approved |
| LYNOZYFIC | Regeneron UK Limited | — | approved |
| VYXEOS LIPOSOMAL (PREVIOUSLY VYXEOS) | Jazz Pharmaceuticals Ireland Limited | — | approved |
| KYPROLIS | Amgen | — | approved |
| UNITUXIN | United Therapeutics Europe Ltd | — | approved |
| PACLITAXEL ACCORD | Accord Healthcare Pty. | — | approved |
| OFEV | Boehringer Ingelheim Pty Ltd | — | approved |
| ARX-IMATINIB | Alphapharm Pty Ltd | — | approved |
| CARMUSTINE | — | Glutathione reductase inhibitor | Approved |
| BEVACIZUMAB | — | Vascular endothelial growth factor A inhibitor | Approved |
| TRABEDERSEN | — | Transforming growth factor beta-2 mRNA antisense inhibitor | Phase 3 |
| TOFACITINIB | — | Janus Kinase (JAK) inhibitor | Phase 3 |
| RINDOPEPIMUT | — | Epidermal growth factor receptor erbB1 vaccine antigen | Phase 3 |
| OMBIPEPIMUT-S | — | Wilms tumor protein vaccine antigen | Phase 3 |
| NIVOLUMAB | — | Programmed cell death protein 1 inhibitor | Phase 3 |
| NIMOTUZUMAB | — | Epidermal growth factor receptor erbB1 inhibitor | Phase 3 |
Additional associated therapies sourced from Open Targets Platform (CC0), linked to NovaPharmaNews drug profiles where matched.
Temozolomide regulatory status (component of combination):
Azeliragon regulatory status: Not yet disclosed. No approval dates, regulatory submissions, or pathway designations (breakthrough, orphan, accelerated approval) provided in available facts.
CAN-201 NDG trial registration: NCT ID 2024-512954-96-00 (note: format suggests Australian trial registry identifier rather than standard NCT format).
Azeliragon is an investigational agent being tested in combination with standard radiation and temozolomide chemotherapy for newly diagnosed glioblastoma, a highly aggressive primary brain cancer. The Phase I/II trial (CAN-201 NDG) is assessing safety and preliminary efficacy of this combination approach.
Lacuna Pharma Pty Ltd, an Australian pharmaceutical company, is sponsoring the CAN-201 NDG Phase I/II study.
The mechanism of action of Azeliragon has not been disclosed in available facts. Additional information from the sponsor or trial documentation would be required to clarify its biological target and mode of action.
Temozolomide is an oral alkylating chemotherapy agent approved globally for glioblastoma. It works by methylating DNA at specific guanine and adenine positions, inducing DNA strand breaks and triggering cancer cell death through apoptosis.
Regulatory approval status for Azeliragon has not been disclosed. The compound is currently in Phase I/II clinical trials; no approvals in the US, EU, Australia, or other major markets have been announced.
The CAN-201 NDG trial is currently active and enrolling patients. It is a Phase I/II open-label study; specific enrollment numbers, sites, and timeline to completion have not been disclosed.
Primary endpoints for the CAN-201 NDG trial have not been disclosed in available facts. The trial is designed to assess safety and preliminary evidence of therapeutic effect; specific efficacy endpoints (progression-free survival, overall survival, response rate) are not yet detailed.
The number of patients enrolled or targeted for enrollment in CAN-201 NDG has not been disclosed in available facts.
Glioblastoma is the most aggressive primary brain cancer in adults, with median overall survival of approximately 15 months despite maximal treatment. Standard therapy (surgery, radiation, temozolomide) has remained largely unchanged for over 20 years, and most patients develop recurrent disease within 12 months, creating a substantial unmet medical need.
The CAN-201 NDG trial adds Azeliragon to the standard combination of radiation and temozolomide. Standard treatment uses radiation and temozolomide alone; this trial investigates whether Azeliragon enhances efficacy or improves outcomes when combined with standard therapy.
Standard-of-care remains radiation plus temozolomide, approved globally and manufactured by multiple companies (Merck Sharp & Dohme, Accord Healthcare, Sandoz, Teva, others). Investigational approaches in development include checkpoint inhibitors, targeted therapies, and tumor-treating fields, though few have successfully improved upon the standard regimen in newly diagnosed disease.
Glioblastoma affects approximately 10,000–15,000 patients annually in developed markets. A therapy demonstrating improved efficacy could command premium pricing given the severe unmet need, poor prognosis, and limited treatment options, though the patient population is relatively small compared to other cancers.
Information about Azeliragon's development history, prior clinical trials, or use in other indications has not been disclosed in available facts. The CAN-201 NDG trial represents the disclosed clinical program for this agent.
The trial is registered under identifier 2024-512954-96-00, which appears to be an Australian trial registry identifier rather than a standard US NCT (ClinicalTrials.gov) number.
Expected completion date, interim analysis timing, and results reporting timeline have not been disclosed in available facts.
No partnerships, licensing agreements, or collaborations have been disclosed for the Azeliragon glioblastoma program. Lacuna Pharma is listed as the sole sponsor of the CAN-201 NDG trial.
Potential regulatory designations (breakthrough therapy, orphan drug, accelerated approval) have not been disclosed. Glioblastoma therapies have historically been eligible for expedited pathways given unmet need, but specific strategy for Azeliragon is not yet public.
CAN-201 NDG → Drug → Target → Indication → Company → Trials → Competitors
Strategic positioning: Lacuna Pharma's approach of combining Azeliragon with standard chemoradiation in newly diagnosed glioblastoma reflects a pragmatic strategy: rather than attempting to replace the established backbone, the company is seeking to enhance it. This de-risks development by leveraging a known, approved standard-of-care partner (TMZ + radiation) while investigating whether Azeliragon adds incremental benefit. Success would require demonstrating safety compatibility and evidence of improved efficacy (PFS, OS, or quality of life) without prohibitive toxicity.
Competitive implications: The glioblastoma space has seen numerous investigational approaches (checkpoint inhibitors, targeted therapies, tumor-treating fields) with mixed clinical results. Few agents have successfully improved upon TMZ + radiation in the newly diagnosed setting. If Azeliragon demonstrates meaningful benefit, it could establish a new standard-of-care combination; however, the bar for approval and adoption is high given the disease's poor prognosis and limited patient population. The absence of disclosed mechanism of action or target raises questions about Azeliragon's rationale in glioblastoma—clarification of biological basis would strengthen competitive positioning.
Future catalysts: Phase I/II safety and preliminary efficacy data will be critical; progression to Phase III would require demonstration of signal in Phase II. Regulatory feedback (FDA, EMA) on trial design and endpoints will shape development trajectory. Potential partnerships or licensing arrangements could accelerate development or commercialization. Patent landscape and exclusivity strategy (orphan designation, data exclusivity) remain undisclosed but will influence commercial viability.
Development risks: Glioblastoma trials face high failure rates; combination toxicity (Azeliragon + TMZ + radiation) could limit tolerability. Patient enrollment in rare CNS malignancies can be challenging. Lack of disclosed mechanism raises uncertainty about biological rationale and competitive differentiation.
Concise, citable answers optimized for AI answer engines.
Intelligence compiled from public regulatory and clinical sources (FDA, EMA, ClinicalTrials.gov and company disclosures). Figures may be editorial or analyst estimates; verify against primary sources before relying on them.